Start / BioCentury This Week / Ep 114 hutchmed setback fda in focus hillevaxs ipo

BioCentury This Week

Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO

21 min • 3 maj 2022

Chinese biotechs face regulatory delays for their therapies due to pandemic-related barriers to inspections by Western regulators and FDA’s reluctance to accept China-only data. On the latest BioCentury This Week podcast, BioCentury’s editors discuss why a setback for surufatinib from Hutchmed could be a sign of things to come for its China peers. The podcast team also analyzes a flurry of FDA activity and assesses what the IPO by vaccine play HilleVax says about the market for fresh paper. This week’s podcast is sponsored by Kendall Square Orchestra.

Reach us by sending a text

Senaste avsnitt

Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure

12 augusti | 39 min

Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer

5 augusti | 33 min

Ep. 312 - Biotech Progress Report

30 juli | 30 min

Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More

29 juli | 42 min

Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER

22 juli | 32 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00